# US 2006/0041022 A1 · Treatment of amyotrophic lateral sclerosis with nimesulide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0041022 A1
- Document ID: US20060041022A1
- Status: Published application
- Kind: A1
- Application number: 11/122,351
- Filed: 2005-05-05
- Published: 2006-02-23
- Earliest claimed: 2002-11-06
- Inventors: Giulio Pasinetti
- Web page: https://patentgrep.com/patent/US20060041022A1

## CPC

- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to methods for delaying the onset or progression of motor impairment associated with amyotrophic lateral sclerosis in a subject by administering to the subject a therapeutically effective amount of nimesulide. It further provides for a means of detecting and monitoring the progression of amyotrophic lateral sclerosis via a protein biomarker for the disease.

## Claims

### Claim 1

A method of delaying the onset of motor impairment associated with amyotrophic lateral sclerosis in a human subject comprising administering, to the subject, an effective amount of nimesulide.

### Claim 2 (depends on 1)

The method of claim 1 where the subject is at risk for developing amyotrophic lateral sclerosis due to a positive family history of amyotrophic lateral sclerosis.

### Claim 3 (depends on 1)

The method of claim 1 where the subject is at risk for developing amyotrophic lateral sclerosis due to the presence of a genetic mutation in the subject that has been positively correlated with amyotrophic lateral sclerosis.

### Claim 4 (depends on 3)

The method of claim 3 wherein the genetic mutation is in the gene encoding superoxide dismutase.

### Claim 5 (depends on 1)

The method of claim 1 where the subject is at risk for developing amyotrophic lateral sclerosis due to an environmental disclosure.

### Claim 6 (depends on 1)

The method of claim 1 where the subject has a diagnosis of amyotrophic lateral sclerosis.

### Claim 7 (depends on 1)

The method of claim 1 where the amount of nimesulide administered is 200 mg per day.

### Claim 8 (depends on 2)

The method of claim 2 where the amount of nimesulide administered is 200 mg per day.

### Claim 9 (depends on 3)

The method of claim 3 where the amount of nimesulide administered is 200 mg per day.

### Claim 10 (depends on 4)

The method of claim 4 where the amount of nimesulide administered is 200 mg per day.

### Claim 11 (depends on 5)

The method of claim 5 where the amount of nimesulide administered is 200 mg per day.

### Claim 12 (depends on 6)

The method of claim 6 where the amount of nimesulide administered is 200 mg per day.

### Claim 13

A method of treating a human subject diagnosed with amyotrophic lateral sclerosis, comprising administering, to the subject, an amount of nimesulide effective in delaying the onset of impairment of a motor function not measurably impaired prior to the initiation of of the treatment.

### Claim 14 (depends on 13)

The method of claim 13 where the amount of nimesulide administered is 200mg per day.

### Claim 15

An assay method for determining the effect of a test agent on the progression of motor function impairment, comprising:
(i) administering, to a mouse which serves as a murine model of motor system disease, the test agent; and
(ii) determining the level of expression, in nervous system tissue of the mouse, of a protein having a molecular weight of about 4.5-6.0 kDa and having a negative charge at pH 9, and
(iii) comparing the level determined in step (ii) with the level of the protein in a control mouse,
wherein a decrease in the level of the protein in the mouse treated with the test agent relative to the level in the control mouse has a positive correlation with the ability of the test agent to delay motor function impairment.

### Claim 16 (depends on 15)

The assay method of claim 15, where the murine model is a model for amyotrophic lateral sclerosis.

### Claim 17 (depends on 16)

The assay method of claim 16, where the murine model has a mutation in the superoxide dismutase gene.

### Claim 18 (depends on 17)

The assay method of claim 17, where the murine model is the SOD1 mutant line.

### Claim 19 (depends on 15)

The assay method of claim 15, where the murine model is a model for spinal cord injury.
